Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 28 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

14 trials in Phase 3/4

Results Transparency

0 of 13 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3

11(40.7%)

Phase 1

9(33.3%)

Phase 4

3(11.1%)

Phase 2

2(7.4%)

N/A

2(7.4%)

27Total

Phase 3(11)

Phase 1(9)

Phase 4(3)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials

NCT07486453Phase 1Not Yet Recruiting

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Role: lead

NCT07384104Phase 1Enrolling By Invitation

Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects

Role: lead

NCT07295418Phase 3Completed

A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

Role: lead

NCT07278830Phase 2Completed

A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

Role: lead

NCT07253584Phase 3Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia

Role: lead

NCT07174830Phase 4Recruiting

Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

Role: lead

NCT07079579Phase 4Not Yet Recruiting

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

Role: lead

NCT07051603Phase 1Recruiting

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

Role: lead

NCT07028320Phase 3Completed

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

Role: lead

NCT07030504Phase 1Active Not Recruiting

To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

Role: lead

NCT06883656Phase 1Completed

The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency

Role: lead

NCT06830954Phase 1Not Yet Recruiting

Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants

Role: lead

NCT06737081Phase 2Recruiting

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Role: lead

NCT06720025Phase 3Completed

Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

Role: lead

NCT06720233Phase 3Completed

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

Role: lead

NCT06016036Phase 3Completed

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Role: lead

NCT06500689Phase 3Completed

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Role: lead

NCT06465264Phase 3Completed

To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Role: lead

NCT05801627Phase 3Completed

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

Role: lead

NCT05782192Phase 3Completed

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Role: lead